The FDA on Tuesday issued a final guidance document to help companies develop generic versions of approved abuse-deterrent opioids. FDA Commissioner Scott Gottlieb said in a statement that the guidance was “one piece of the FDA’s ongoing work aimed at finding solutions to combat the opioid crisis.”
Read more via MedPage Today here.